The encyclopedia · R&D & Science · Technical decision · 2012–2020
CRISPR-Cas9 turned a bacterial immune system into programmable gene editing
Researchers repurposed a microbe's own DNA-cutting defense into a tool where a guide RNA decides exactly where to cut.
University of California Berkeley · Broad Institute
the move
Bacteria defend against viruses using CRISPR arrays: short RNA pieces remember past invaders and guide a nuclease to matching DNA, which the cell then cuts. In 2012, Emmanuelle Charpentier and Jennifer Doudna showed this system could be programmed: by supplying a designed guide RNA, Cas9 could be directed to cut chosen DNA sequences in a test tube.
The breakthrough was the handle. Where previous editing tools (zinc fingers, TALENs) required engineering a new DNA-binding protein for every target—slow and expensive—CRISPR-Cas9 only requires synthesizing a new 20-nucleotide guide RNA. Retargeting went from weeks of protein engineering to days of RNA synthesis.
The 2014 Nature review, written by Doudna and Charpentier with their collaborators, laid out how the two-RNA structure could be simplified and how the mechanism could be harnessed for genome engineering in living cells. The combination of simplicity, precision and low cost made it the dominant gene-editing method within a few years.
why it works
- Guide RNA design replaces protein engineering, so retargeting is cheap and fast.
- The system is naturally programmable—the specificity lives in a short RNA sequence anyone can synthesize.
- One nuclease works for nearly any target, so the tool is general rather than bespoke.
- The cell's own repair machinery does the editing, so no additional editing engine is needed.
what transfers
The hardest part of a tool is often already solved in nature—the clever move is finding the biological mechanism and adding a human-controllable handle.
what came after
CRISPR-Cas9 became the standard gene-editing tool across biology, medicine and agriculture, and Doudna and Charpentier received the 2020 Nobel Prize in Chemistry. A fierce patent dispute followed between UC Berkeley and the Broad Institute over CRISPR use in eukaryotic cells, while clinical trials for sickle-cell disease and other genetic conditions moved from promise to approved therapies.
references
spotted an error? The archive wants to know.